

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 5/08, 5/10, A61K 48/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/17784</b> <b>(43) International Publication Date:</b> 30 April 1998 (30.04.98)
<b>(21) International Application Number:</b> PCT/CA97/00774 <b>(22) International Filing Date:</b> 17 October 1997 (17.10.97)  <b>(30) Priority Data:</b> 60/028,692 18 October 1996 (18.10.96) US  <b>(71) Applicant (for all designated States except US):</b> UNIVERSITE LAVAL [CA/CA]; Cité Universitaire, Québec, Québec G1K 7P4 (CA).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> TREMBLAY, Jacques, P. [CA/CA]; 579 du Sous-Bois Street, Bernière, Québec G7A 1C2 (CA).  <b>(74) Agents:</b> DUBUC, Jean, H. et al.; Goudreau Gage Dubuc & Martineau Walker, The Stock Exchange Tower, Suite 3400, 800 Place Victoria, P.O. Box 242, Montréal, Québec H4Z 1E9 (CA).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHOD FOR IN VITRO PRECONDITIONING OF MYOBLASTS BEFORE TRANSPLANTATION  <b>(57) Abstract</b>  A method of pretreating healthy donor's myoblast cultures with growth or trophic factors like basic fibroblast growth factor (bFGF) and with concanavalin A on transplantation to subjects suffering of myopathy like muscular dystrophy is disclosed and claimed. Recipient muscles show a higher percentage of functional cells, a four-fold increase, demonstrated by the higher incidence of dystrophin-positive fibers, and does not require previous preconditioning of recipient muscles by irradiation or toxin administration. The recipient subjects were immunosuppressed with FK 506. When growing myoblasts with 20 µg/ml concanavalin A or 100 ng/ml TPA for two to four days, migration of donor cells in recipient tissue was increased by 3 – 4 fold. This suggests that, when using primary cultures, metalloproteases are secreted by fibroblasts, resulting in a greater degradation of the extracellular matrix. Both metalloproteases and bFGF appear beneficial for the success of the transplantation. The use of recombinant myoblast expressing metalloproteases is also contemplated.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

**TITLE OF THE INVENTION**

METHOD FOR IN VITRO PRECONDITIONING OF MYOBLASTS BEFORE TRANSPLANTATION

5

**FIELD OF THE INVENTION**

The present invention is a method for preconditioning healthy donor's myoblasts *in vitro* before transplantation thereof in compatible patients suffering of recessive myopathies, particularly of muscular dystrophy. This *in vitro* preconditioning improves the success of the transplantation while not requiring an *in vivo* preconditioning of the patient's muscle by irradiation or by administering muscular toxin.

**BACKGROUND OF THE INVENTION**

Duchenne muscular dystrophy (DMD) is a progressive disease characterized by the lack of dystrophin under the sarcolemmal membrane<sup>6,19,28,37</sup>. One possible way to introduce dystrophin in the muscle fibers of the patients to limit the degeneration is to transplant myoblasts obtained from normal subjects<sup>30,34,35</sup>.

- 2 -

Several groups have tried myoblast transplantations to DMD patients but poor graft success was observed<sup>17,22,24,38</sup>. Even in experimental myoblast transplantation using mdx mice, an animal model of DMD<sup>10,25,29</sup>, large amount of dystrophin-positive fibers were observed only when nude mdx mice were previously irradiated to prevent regeneration of the muscle fibers by host myoblasts<sup>32,43</sup>. High percentage of dystrophin-positive fibers was also observed in mdx mice immunosuppressed with FK 506 and in SCID mice, in both cases muscles were previously damaged by notexin injection and irradiated<sup>23,27</sup>. These results indicate that to obtain successful myoblast transplantation, it is necessary to have not only an immunodeficient mouse or a mouse adequately immunosuppressed but also a host muscle which has been adequately preconditioned. It is, however, impossible in clinical studies to use damaging treatments such as marcaine, notexin and irradiation. If good myoblast transplantation results can be obtained without using such techniques, this would be very helpful for myoblast transplantation in humans.

Recently there has been an increasing interest on the effects of basic fibroblast growth factor (bFGF) and other growth factors on myoblast cultures and myoblast cell lines<sup>1,4,5</sup>. Basic FGF has been

- 3 -

reported to both stimulate proliferation and inhibit differentiation of skeletal myoblasts in vitro<sup>15,16</sup>. Other growth or trophic factors like insulin growth factor I, transferrin, platelet-derived growth factor, epidermal growth factor, adrenocorticotrophin and macrophage colony-stimulating factor as well as C kinase proteins activators or agonists by which the effect of bFGF is mediated<sup>20</sup> may also have similar or even better effects than bFGF on the success of myoblast transplantation<sup>7</sup>.

10 The use of these stimulating properties to enhance the success of transplantation by *in vitro* preconditioning of donor's cells and to replace at least partially the use of previously known methods of *in vivo* preconditioning of recipients' cells has never been

15 suggested before.

Furthermore, it has been recently published by Overall and Sodek (1996) that concanavalin A increased the secretion of metalloproteases by fibroblasts. Since these enzymes are believed to be

20 present in primary myoblasts cultures, and since they may be responsible for the degradation of the extracellular matrix, it would be desirable to precondition the myoblasts in the presence of both a growth factor and an inducer of the production of

25 metalloproteases, to increase the distance of migration

- 4 -

of the transplanted myoblasts and to increase the number of fused myoblasts expressing muscle functional proteins. An attractive alternative would be to use donor myoblasts wherein a gene expressing a metalloprotease is inserted.

5 Metalloproteases are enzymes necessary for tumor invasion, for cell migration<sup>45</sup>, and for restructuration of extracellular matrix during normal tissue remodelization<sup>46</sup>. Matrilysine and gelatinase A are metalloproteases involved in tissue invasion of a plurality of cancer types<sup>47</sup>. The presence of gelatinase A in its active form has been correlated with the generation of new muscle fibers, during muscle degeneration-regeneration process<sup>48</sup>. It has been shown that the activity of gelatinase A can induce cell migration by cleaving laminin-5, an extracellular matrix component, thereby exposing a pro-migratory cryptic site<sup>49</sup>.

From the foregoing, it is really apparent that a compound capable of stimulating the expression of a metalloproteases involved in an extra-cellular restructuration, such as phorbol ester or concanavalin A, would be useful to increase the success of transplantation of myoblasts. Since metalloproteases appear to be secreted in the culture medium, it would

- 5 -

also be useful to test if metalloproteases such as matrilysine, gelatinase A, or other metalloproteases of the same class, could be injected directly with myoblasts in recipient muscle for the same purpose.

5     **STATEMENT OF THE INVENTION**

          The present invention relates to a method of *in vitro* preconditioning of myoblasts harvested from healthy donor's biopsy prior to their transplantation in patients affected by recessive myopathies, particularly  
10     by Duchenne muscular dystrophy (DMD). In a DMD animal model (mdx), compatible donor mouse myoblasts were grown in culture with muscular growth or trophic factors, particularly, basic Fibroblast Growth Factor (bFGF), before transplanting them in muscles of mdx mice without  
15     any previous damaging treatment. A four fold increase in the percentage of muscle fibers expressing dystrophin, which is indicative of functional muscle cells, was obtained with pretreatment with bFGF. These experimental results are expected to verify in naturally occurring  
20     dystrophy or other types of recessive myopathies in animal and human subjects, since the mdx mouse is an animal model wherein muscular dystrophy is naturally occurring.



- 6 -

Furthermore, culturing the myoblasts in the presence of concanavalin A during two to four days prior to transplantation increases by 3 to 4 fold the distance of migration of the transplanted cells into the recipient tissue. Another inducer of the expression of metalloproteases, phorbol ester has been also used and reproduced the same result as for concanavalin A (increase migration and increased number of fused cells expressing a reporter gene). Recombinant myoblasts expressing metalloproteases also produced the same result.

It is therefore an object of the invention to provide a method wherein cultured myoblasts are transplanted in the presence of a metalloprotease. The production of metalloproteases may be induced during the period of culturing of primary myoblast cultures with or without the preconditioning step in the presence of muscle growth factor. Alternatively, the metalloproteases may be expressed by recombinant myoblasts or injected concurrently with the transplanted myoblasts. Transplantation of cells along with a matrix degrading amount of metalloproteases and transplantation of recombinant cells expressing these enzymes are not limited to myoblasts, but could rather be adapted to any type of transplanted cells.

- 7 -

In accordance with the present invention is provided a method of increasing the number of transplanting donor's myoblasts which are capable of fusing with the myoblasts of a recipient individual suffering of a myopathies, which comprises the steps of:  
5 growing said donor's myoblasts in an appropriate culture medium in the presence of fibroblasts and of an agent inducing an increased secretion of an enzyme involved in extracellular matrix destruction prior to injecting said  
10 medium, donor's myoblasts and fibroblasts to said recipient individual.

Alternatively is provided a method, wherein the donor's myoblasts are recombinant myoblasts expressing a gene coding for said enzyme.

15 Is further provided a method which comprises reproducing one of the above methods, and combining to the inducer agent a growth or trophic factor to increase the multiplication of said healthy myoblasts.

20 In a specific embodiment, said myopathy is Duchenne muscular dystrophy.

In a preferred embodiment, donor's myoblasts consist of a primary myoblast culture obtained from culturing of an enzymatic cell dispersion of  
25 donor's muscle biopsy.

- 8 -

It has been observed that growing of primary cultures of donor's myoblasts, which contain fibroblasts, in the presence of a growth or trophic factor is an *in vitro* preconditioning step that replaces  
5 at least in part an *in vivo* preconditioning of said recipient individual's muscular tissue by irradiation or by administering a muscular toxin.

The growth or trophic factor is selected from the group consisting of basic fibroblast growth  
10 factor (bFGF), insulin growth factor I, transferrin, platelet-derived growth factor, epidermal growth factor, adrenocorticotrophin, macrophage colony-stimulating factor, protein kinase C activators, agonists thereof, and combinations thereof.

15 In a preferred embodiment, the growth or trophic factor is basic fibroblast growth factor (bFGF).

In a more preferred embodiment, the primary myoblast culture is grown in the presence of 100 ng of recombinant human bFGF per milliliter of culture medium  
20 for a period of time of about 48 hours before transplantation, whereby a four fold increase of the number of functional muscular cells is obtained.

In still a preferred embodiment, the enzyme involved in the extracellular matrix destruction is a

- 9 -

metalloprotease such as matrilysine and gelatinase A and the inducer agent is phorbol ester or concanavalin A.

In a most preferred embodiment, the inducing agent is concanavalin A (Con A).

5 In a specific embodiment, growing primary myoblast cultures in the presence of 20  $\mu\text{g/ml}$  of Con A for 48 hours resulted in a 3-4 fold increase of the migration distance of transplanted myoblasts and of fused myoblasts.

10 In the most preferred embodiment, primary myoblast cultures are cultured for two days in the presence of both Con A and bFGF, which would result in a superior transplanting success when compared to each treatment alone.

15 **DESCRIPTION OF THE INVENTION**

Although the present trend on research for the treatment of DMD seems to be towards gene therapy, rather than cell therapy, there is still a great deal of work to be done in animal models before either approach,  
20 or a mixture of both approaches will be required for the treatment of inherited myopathies such as DMD<sup>32,34</sup>.

No satisfactory level of dystrophin expression was obtained following myoblast transplantation not only in clinical trials but also in

- 10 -

animal experiments not using irradiation<sup>33</sup> combined with marcaine or notexin destruction of the muscle<sup>26,27</sup>. These techniques are, however, too damaging, too invasive or too risky to be used in clinical trials. Basic FGF has  
5 been reported to both stimulate proliferation and inhibit differentiation of skeletal myoblasts by suppressing muscle regulatory factors such as MyoD and myogenin<sup>12,41</sup>. Expression of bFGF has been examined in regenerating skeletal muscles by immunohistochemistry  
10 and in situ hybridization, and found to be up-regulated compared to non-injured muscles<sup>3,11</sup>. Increased skeletal muscle mitogens have also been observed in homogenates of regenerating muscles of mdx mice<sup>3</sup>. There are increased levels of bFGF in extracellular matrix of mdx  
15 skeletal muscles<sup>13</sup>, mdx satellite cells associated with repair<sup>3</sup> and such cells respond more sensitively to exogenous addition of bFGF<sup>14</sup>. There is a high degree of homology between bFGF from various species<sup>2</sup> therefore recombinant human bFGF is active on mouse cells<sup>9</sup>. In the  
20 present series of experiments, myoblasts were pretreated with recombinant human bFGF to increase their proliferation and to verify whether such treatment which is less invasive could have beneficial effects on myoblast transplantation.

- 11 -

In our experiments, primary myoblast cultures from the same donors were grown with or without bFGF and transplanted simultaneously to both *tibialis anterior* (TA) muscles of the same mice. This seems to be  
5 a good model to verify the effect of bFGF because the same primary myoblast cultures, the same grafting conditions and the same immunosuppressive state were used. Comparing both TA muscles, in all treated mdx mice, the percentage of  $\beta$ -galactosidase-positive fibers  
10 (this enzyme being a reporter gene) were significantly higher in left TA muscles cultures (with bFGF) than in right TA muscles cultures (without bFGF). In the muscles grafted with myoblasts grown with bFGF, the average percentage of hybrid fibers was 34.4%, with two muscles  
15 containing over 40% of donor or hybrid fibers. These are the best results ever reported following myoblast transplantation without notexin or irradiation treatment.

In the present study, myoblasts were  
20 incubated with bFGF during 48 hours and about 5 millions of these cells (about 1.75 million myogenic cells) were injected in one TA muscle. The same number of myoblasts not incubated with bFGF was injected in the control contralateral TA muscle. The higher percentage of  
25  $\beta$ -galactosidase/ dystrophin-positive fibers was

- 12 -

therefore not the consequence of a higher proliferation of the myoblasts in vitro before the transplantations.

Our in vitro results indicate that an incubation during 2 days with bFGF did not significantly  
5 modify the total number of cells and the percentage of myogenic nuclei. Basic FGF did, however, significantly inhibit the fusion of myoblasts in vitro. This resulted in a small but significant increase (35%) of the percentage of myoblasts among mononuclear cells. This  
10 increase seems too small to account alone for the more than four fold increase of effectiveness of myoblast transplantation produced by bFGF. Recently both Partridge<sup>7</sup> and Karpati's<sup>24</sup> group reported that a high percentage (up to 99% in Partridge's results) of the  
15 myoblasts injected in a mouse die within 5 days. This dramatic result does not seem attributable to immunological problems since it was observed following autotransplantation<sup>24</sup> or transplantation in nude mice<sup>7</sup>. In our experiments, although there were slightly more  
20 cells surviving three days post-transplantation for the cultures treated with bFGF, the difference did not reach a significant level and does not seem to account alone for the 4 fold beneficial effect observed 30 days post transplantation.

- 13 -

Basic FGF is thought to regulate myogenesis during muscle development and regeneration *in vivo*<sup>3</sup>. The increase percentage of muscle fibers containing the donor gene produced by the addition of bFGF may seem surprising since bFGF was reported to inhibit differentiation of myoblasts *in vitro*<sup>1,13</sup>. Basic FGF is, however, one of many growth factors which are liberated following muscle damage<sup>7</sup>. These factors, all together, certainly increase myoblast proliferation and eventually muscle repairs. We have also observed that following a two day incubation with bFGF of primary myoblast cultures, myoblast fusion occurred within a few days after removal of bFGF (data not shown). The inhibition by bFGF on myoblast fusion is therefore not irreversible. Basic FGF is already at an increased level in mdx muscle, therefore it is not surprising that direct intramuscular injection did not increase the fusion of the donor myoblasts with the host fibers. In fact, bFGF injected directly in the muscle probably stimulates the proliferation of the host as well as the donor myoblasts and therefore do not favour the donor myoblasts. On the contrary, preliminary stimulation by bFGF of the donor myoblasts in culture may favour these myoblasts to proliferate more and eventually participate more to muscle regeneration than the host myoblasts.



- 14 -

Though bFGF stimulates the fibroblasts, which an inconvenience for primary myoblast cultures, incubation of myoblast primary culture during only 48 hours with bFGF did not adversely affect our transplantation results and did on the contrary improve them. If primary myoblast cultures were made fibroblast-free by sub-cloning, it is envisageable to precondition the donors' myoblasts for a longer time and increasing this way the number of cells to be transplanted from a relatively small biopsy.

Although the results obtained following transplantation of myoblasts grown with bFGF are not as good than those obtained using irradiation and notexin<sup>27</sup>, these results are nevertheless important because no technique to destroy the muscles was used. The proposed in vitro preconditioning method might therefore be used in complete replacement of such in vivo damaging pretreatment of recipient cells, or at least in partial replacement thereof, which will result in a substantial diminution of undesirable effects. The effects of many growth factors and trophic factors on myoblast culture have been reported, it is possible that other factors such as insulin growth factor I, transferrin, platelet-derived growth factor, epidermal growth factor, adrenocorticotrophin and macrophage colony-stimulating

- 15 -

factor may also have similar or even better effects than bFGF on the success of myoblast transplantation<sup>7</sup>. Furthermore, since the effect of bFGF is mediated by proteins kinase C, pharmacological agents used to enhance the activity of these enzymes (like phorbol esters) or mimicking the effect thereof (agonists) might also be used for preconditioning myoblasts. Therefore, at least one of these factors can be used alone or in combination with or without bFGF to enhance the success of myoblast transplantation. While the mechanism involved remains speculative, bFGF seems to improve the long term viability, multiplication and fusion of myoblasts. Our results suggest that pretreatment of myoblasts with bFGF may be one procedure that may increase the success of myoblast transplantation in DMD patients.

The present invention will be further described by way of the following Examples and Figures, which purpose is to illustrate this invention rather than to limit its scope.

#### **BRIEF DESCRIPTION OF THE FIGURES**

Figure 1 shows cross sections of TA muscle of mdx mice 28 days after injection of the transgenic myoblasts. Pairs of serial sections from 3 different

- 16 -

muscles of three mice are illustrated. Panels a and b illustrate sections of muscles injected with myoblasts grown without bFGF. Panels c to f illustrate sections of muscles injected with myoblasts grown with bFGF. In each pair, one section was stained for  $\beta$ -galactosidase (panels a, c and e). The other section of the pair was immunostained for dystrophin (panels b, d and f). The muscles injected with myoblasts grown in presence of bFGF contained much more  $\beta$ -galactosidase and dystrophin positive fibers than muscles injected with myoblasts grown without bFGF. Most muscle fibers expressing  $\beta$ -galactosidase were dystrophin-positive. In each pair of panels, the same muscle fibers are identified by the same numbers. Scale bar is 100  $\mu$ m.

Figure 2 shows the number of muscle fibers positive for X-Gal counted after an injection of 500 000 donor's cells in one site of the *tibialis anterior* of recipient mice. Imm 7 neo: expresses neomycin. Imm 7 Matrilysine: expresses neomycin and matrilysine. Tn I  $\beta$ gal: untreated transgenic mouse myoblasts expressing  $\beta$ -Gal. Tn I  $\beta$ Gal + TPA: transgenic mouse myoblasts /  $\beta$ -Gal treated with phorbol ester.

- 17 -

**EXAMPLE 1****MATERIALS AND METHODS****Myoblast cultures**

Primary myoblast cultures were established from muscle biopsies of newborn transgenic mice<sup>26</sup>. The founder mouse (TnI Lac Z1/29) was provided by Dr. Hasting (McGill University, Montreal, Canada) onto the CD1 background and was reproduced in our laboratory. This transgenic mouse expresses the  $\beta$ -galactosidase gene under the control of the promoter of the quail fast skeletal muscle troponin I gene<sup>16</sup>. Blue muscle fibers are revealed in these transgenic mice following incubation with a substrate, 5-brom-4-chlor-3-indolyl- $\beta$ -D-galactopyronoside (X-gal) (Boehringer Mannheim Canada, Laval, Canada). Before starting myoblast cultures, it was necessary to identify transgenic newborns by X-gal staining of a small muscle biopsy because heterozygote transgenic mice were used as parents. Myogenic cells were released from skeletal muscle fragments of the transgenic newborns by serial enzyme treatments. First, a one hour digestion was done with 600 U/ml collagenase (Sigma, St-Louis, Mo, USA). This was followed by a 30 minute incubation in Hanck's

- 18 -

balanced salt solution (HBSS) containing 0.1% w/v trypsin (Gibco Lab, Grand Island, NY, USA). Satellite cells were placed in 75 cm<sup>2</sup> culture flasks (Coster, Cambridge, Ma, USA) in proliferating medium, i.e. 199 medium (Gibco Lab.) with 15% fetal bovine serum (Gibco Lab.), 1% penicillin (10,000 U/ml) and 1% streptomycin (10,000 U/ml).

#### Myoblast transplantation

One day after starting culture, the culture medium of some flasks was replaced by medium containing 100 ng/ml human recombinant bFGF (Sigma). Three days after starting culture, myoblasts were detached from the flasks with 0.1% trypsin followed by three suspensions in HBSS and centrifugations (6500 RPM, 5 minutes). The final cell pellet was diluted in only 40 µl of HBSS.

Seventeen C57BL/10ScSn mdx/mdx mice (mdx mice) approximately one month old were used for this experiment. This work was authorized and supervised by the Laval University Animal Care Committee and was conducted according to the guidelines set out by the Canadian Council of Animal Care.

The mdx mice were divided in three groups. Six mdx mice of one group were grafted in both tibialis anterior (TA) muscles: myoblasts grown with bFGF were

- 19 -

injected in the left TA and myoblasts grown without bFGF were injected in the right TA. Myoblasts grown without bFGF were injected in only the left TA of six other mdx mice. These six mdx mice were then injected intramuscularly four times (after grafting 0, +1, +4 and +6 days) either with 10  $\mu$ l of bFGF (100 ng/ml, 3 mice) or with 10  $\mu$ l of HBSS (3 mice). The last five mice were grafted in both TA muscle with normal CD1 mouse myoblasts infected with replication defective retroviral vector LNPOZC7 (gift from Dr C. Cepko, Harvard, Boston, MA) which contains the LacZ gene. The left TA muscles were injected with 4 million myoblasts grown with bFGF, while the right TA muscles were injected with 4 million myoblasts grown without bFGF. Three days after grafting, these 5 mice were sacrificed to detect the number of  $\beta$ -galactosidase positive cells which survived in each TA muscle. The numbers of  $\beta$ -galactosidase positive cells were counted in 8  $\mu$ m sections obtained at every 160  $\mu$ m throughout the muscle. The total number of cells counted was multiplied by 20 to obtain an estimate of the number of surviving cells and a correction was made to account for the percentage of unlabelled cells in cultures with and without bFGF.

For the myoblast injection, the mice were anesthetized with 0.05 ml of a solution containing 10

- 20 -

mg/ml of ketamine and 10 mg/ml xylazine. The skin was opened to expose the TA muscle. The myoblast suspension was taken up into a glass micropipette with 50  $\mu$ m tip (Drummond Scientific Company, Broomall, Pe, USA). The TA muscle was injected at 10 sites with a total of about 5 million cells. The skin was then closed with fine sutures. FK 506 (Fujisawa Pharmaceutical Co Ltd, Osaka, Japan) was administered at 2.5 mg/kg to immunosuppress the animals. Alternatively, the immunosuppressive treatment can be made by other pharmacological agents like cyclosporin (Sandoz), RS61443 (Syntex) or rapamycin (Wyeth-Ayerst) <sup>42</sup>.

#### Muscle examination

Three or twenty-eight days after myoblast transplantation, the mice were sacrificed by intracardiac perfusion with 0.9% saline under deep anesthesia of 10 mg/ml ketamine and 10 mg/ml xylazine. The TA muscles were taken out and immersed in a 30% sucrose solution at 4°C for 12 hours. The specimens were embedded in OCT (Miles Inc, Elkhart, IN, USA) and frozen in liquid nitrogen. Serial cryostat sections (8  $\mu$ m) of the muscles were thawed on gelatin coated slides. These sections were fixed in 0.25% glutaraldehyde and stained in 0.4 mM X-gal in a dark box overnight (12 hours) at

- 21 -

room temperature to detect the muscle fibers containing  $\beta$ -galactosidase. Dystrophin was detected on adjacent cryostat sections by an immunoperoxidase technique with a sheep polyclonal antibody against the 60 KD dystrophin fragment (R27, Genica Co, Boston, Ma, USA) and the peroxidase activity was revealed by a 10 minute incubation with 3,3' diaminobenzidine (DAB, 0.5 mg/ml, Sigma) and hydrogen peroxidase (0.015%).

#### Desmin staining

The primary cultures were washed with PBS and fixed with 100% methanol at -4°C. They were then washed again 3 times with PBS and incubated 1 hr with a mAb anti-human desmin (Dako, Copenhagen, Denmark) diluted 1/50 with PBS containing 1% blocking serum (i.e. 0.33% rabbit serum, 0.33% horse serum and 0.33 fetal calf serum). They were washed 3 times with PBS with 1% blocking serum and incubated 1 hr with a 1/100 dilution (in PBS with 1% blocking serum) of a rabbit anti-mouse immunoglobulin (Dako). Following 3 washes with PBS, the peroxidase activity was revealed with DAB as for dystrophin immunohistochemistry.



- 22 -

## RESULTS

Myoblasts from muscle biopsies of transgenic mice expressing  $\beta$ -galactosidase under a muscle specific promoter were grown with or without bFGF and injected in mdx muscles not previous irradiated or damaged with notexin. A month later, the animals were sacrificed and the injected muscles were examined for the presence of  $\beta$ -galactosidase and dystrophin. Many positive muscle fibers were observed. In our previous experiments, muscles of mdx mice which did not receive injections of transgenic myoblasts remained completely devoid of  $\beta$ -galactosidase-positive fibers<sup>22</sup>. Therefore all  $\beta$ -galactosidase-positive muscle fibers observed in grafted mdx muscles are resulting from the fusion of some donor myoblasts among themselves (donor's fibers) or with the host myoblasts (hybrid fibers). In serial muscle sections, most of the  $\beta$ -galactosidase-positive muscle fibers were observed to be also dystrophin-positive (Fig. 1). In all biopsied TA muscles, the number of  $\beta$ -galactosidase-positive muscle fibers was counted and expressed as a percentage of the total number of fibers in a cross section. The sections containing of the maximum percentage of  $\beta$ -galactosidase-positive muscle fibers were selected for each muscle. In

- 23 -

mdx mice grafted in both TA muscles, the percentage of  $\beta$ -galactosidase-positive muscle fibers in the left TA muscle (grafted with myoblasts grown with bFGF) was compared with that in the right TA muscle (grafted with myoblasts grown without bFGF) of the same mouse (Table 1). Without notexin and irradiation, only a low percentage of hybrid or donor muscle fibers were observed in the right TA muscle i.e. the mean number of  $\beta$ -galactosidase-positive fibers per muscle cross section was 156.3 giving a mean percentage of  $\beta$ -galactosidase-positive fibers of 8.396. The left TA muscles contained, however, significantly more hybrid or donor muscle fibers, i.e. the mean number of  $\beta$ -galactosidase-positive fibers per muscle cross section was 773.7 thus giving a mean percentage of  $\beta$ -galactosidase-positive fibers equal to 34.4% (Fig. 1). This is more than a four fold increase in the efficacy of myoblast transplantation produced by the addition of bFGF to the culture medium.

We have also investigated whether the beneficial effect of bFGF could be obtained by injecting it directly in the muscle at 4 intervals after myoblast transplantation. No significant difference in the percentage of hybrid or donor muscle fibers (i.e.  $\beta$ -galactosidase positive fibers) was observed between the groups which received intramuscular injections of

- 24 -

bFGF and those which received HBSS injections (control) (Table 2). The percentage of  $\beta$ -galactosidase positive muscle fibers was, however, higher following repeated injection of HBSS (14.8%) or of bFGF (15.9%) than  
5 following injection of myoblasts alone grown without bFGF (Table 1, 8.3%). This may be due to damage produced by the repeated injections which may increase the regeneration process.

It has been reported recently by Huard et  
10 al.<sup>21</sup> and by Beauchamp et al.<sup>7</sup>, that a high percentage of the myoblasts injected in a muscle died within the first few days following their transplantation. To examine whether the increase efficiency of myoblast transplantation following culture with bFGF could be due  
15 to a reduced cell death, we have labelled normal CD1 primary cultures grown with or without bFGF with a retroviral vector containing the  $\beta$ -galactosidase gene under an LTR promoter. Normal myoblasts were labelled with a retroviral expressing  $\beta$ -galactosidase because  
20 only mature myoblasts and myotubes of transgenic TnI LacZ 1/29 can express  $\beta$ -galactosidase. With labelling using a retroviral vector a higher percentage of the cells in the primary culture expressed the reporter gene. The retrovirally labelled cells were then injected  
25 in a muscle of 5 mice. We examined the number of

- 25 -

β-galactosidase positive cells 3 days after their transplantation. In all 5 mice, the number of the cells was not significantly higher in left TA muscles (with bFGF) ( $3.29 \pm 1.54 \times 10^5$  cells) than in right TA muscles (without bFGF  $2.13 \pm 0.40 \times 10^5$  cells). Note that since  $4 \times 10^6$  cells were injected in each muscle, there is only 5.3% of the injected cells surviving at 3 days without bFGF while only 8.2% of the injected cells survived with bFGF.

10                   To try to understand the beneficial effects of bFGF on myoblast transplantation, we examined the effect of a short stimulation (2 days) with 100 ng/ml bFGF on primary myoblast cultures. The total number of cells in each flask was not significant different ( $31.9 \pm 6.8 \times 10^6$  with bFGF  $n = 5$ ,  $30.0 \pm 5.8 \times 10^6$  without FGF  $n = 9$ , unpaired t-test:  $p = 0.573$ ). The myoblasts and myotubes were then identified by revealing desmin by immunoperoxidase. In these cultures, there was no difference in the percentage of myogenic nuclei (nuclei in myoblasts and in myotubes) between the two groups of cultures (Table 3, line 1). More myogenic cells were however fused in the absence of bFGF (Table 3, line 2). There was an higher percentage of the total nuclei (including myoblasts, myotubes and fibroblasts) which were myoblast nuclei in cultures containing bFGF

- 26 -

(Table 3, line 3). The increase of myoblasts was more clear when the percentage of myoblasts was calculated among mononuclear cells (excluding the myotubes) (Table 3, lines 4 and 5). This was however only a 35% increase.

5 Table 1: Effect of culture with or without bFGF on the formation of muscle fibers containing donor's gene in mdx mice

		no bFGF (right TA muscle)	with bFGF (left TA muscle)
	No of mdx mice	No (%) of $\beta$ -gal. positive fibers	No (%) of $\beta$ -gal. positive fibers
10	1	170 (11.0)	514 (19.3)
	2	259 (11.9)	438 (20.4)
	3	259 (13.1)	1007 (37.4)
	4	57 (4.1)	695 (34.0)
	5	139 (6.1)	848 (43.8)
15	6	54 (3.6)	1140 (51.7)
	Mean $\pm$ SD	156.3 $\pm$ 91.5 (8.3 $\pm$ 4.2) #	773.7 $\pm$ 275.8 (34.4 $\pm$ 12.8) #

# Paired t-test indicated a significant difference (p < 0.05)

- 27 -

Table 2: Effects of bFGF on primary myoblast culture

		no bFGF (mean $\pm$ SD)	with bFGF (mean $\pm$ SD)	sign
5	1) % of myoblast and myotube nuclei relative to total nuclei	34.5 $\pm$ 5.3	35.1 $\pm$ 4.8	0.81
	2) % of myotube nuclei relative to total myotube and myoblast nuclei	40.8 $\pm$ 8.0	11.5 $\pm$ 6.6	0.0001
10	3) % myoblast nuclei relative to total nuclei	21.1 $\pm$ 3.6	30.9 $\pm$ 3.8	0.0001
	4) % myoblast nuclei relative to non myotube nuclei	23.9 $\pm$ 5.4	32.2 $\pm$ 4.1	0.001
15	5) % of non-myoblast nuclei relative to non myotube nuclei	76.1 $\pm$ 5.4	67.8 $\pm$ 4.1	0.001

- 28 -

Table 3: Effect of intramuscular injections of bFGF in mdx mice

	No (5%) of β-gal. positive fibers	Mean±SD
5	HBSS IM injections	
	1	180 (12.4)
	2	421 (14.1)
	3	515 (18.0)
10	bFGF IM injections	
	1	176 (7.4)
	2	482 (24.1)
	3	211 (16.3)

372.0±172.8 (14.8±2.9)	
289.7±167.5 (15.9±8.4) T test indicated no significant difference (p>.05)	

- 29 -

**EXAMPLE 2**

The above results can be extrapolated to an *in vivo* utility and verified in patients suffering of muscular dystrophy. The healthy donors and DMD recipients should be matched, if possible, upon their compatibility for the MHC (HLA)-class I (A,B,C) and -class II (Dr) antigens. The dystrophic patients should undertake an immunosuppressive treatment by being administered, for example, FK 506, cyclosporin, RS61443 or rapamycin. Donors' biopsy would then be treated substantially in accordance with the procedures given in Example 1 with regard to mice myoblasts. The success of the transplantation might be monitored by measuring the incidence of dystrophin-positive fibers from a biopsy obtained from the site of transplantation and by evaluating the resulting increase of muscular strength<sup>39</sup>.

**EXAMPLE 3**

Myoblasts infected with a retrovirus expressing a beta-galactosidase gene have been cultured for four days in the presence or absence of 20 $\mu$ g/ml concanavalin A, a lectine which stimulates the expression of metalloproteases. These myoblasts were then injected in one single site of the anterior tibialis muscle of eight mice, in order to verify the



- 30 -

degree with which the transplanted cells are capable of migrating through the recipient tissue. After thirty days, mice were sacrificed and the muscle tissue was harvested, frozen and 10 $\mu$ m thick slices were mounted on slides. The presence of beta-galactosidase was revealed with X-Gal. Labelled cells were observed at a distance which is 3 to 4 fold greater in the mice muscle treated with concanavalin A. Concanavalin A is known to induce the secretion of metalloproteases by the fibroblasts present in the primary cultures. Therefore, the presence of metalloproteases in the preconditioning medium or during the transplantation is beneficial to the spreading of the transplanted cells from the site of the injection through the recipient muscle tissue.

Three experiments confirmed that an increased expression of enzymes involved in the destruction of the extracellular matrix indeed increases the migration of myoblasts.

First experiment: Myoblasts obtained from CMVLacZ mice (expressing a Beta-galactosidase gene) were cultured for two (2) days in the presence of twenty (20)  $\mu$ g/ml concanavalin A, a lectine which stimulates the expression of metalloproteases. When these myoblasts were injected in the anterior tibialis muscle of recipient mice, the migration of transplanted cells was

- 31 -

increased by three (3) fold comparatively to myoblasts having not received the concanavalin treatment.

Second experiment: primary cultures of myoblasts were obtained from transgenic mice (TnI- $\beta$ Gal + TPA). Myoblasts were cultured for two (2) days in the presence of phorbol ester (TPA 100 ng/ml) which also stimulates the expression metalloproteases. These treated myoblasts generated four times more fibers on an area four fold greater than for transplanted myoblasts injected from a non-treated preparation (See figure 2; n = 5 mice).

Third experiment: To verify if metalloproteases are really involved in the increased spread of transplanted myoblasts, we have stably transfected an immortalized myoblast cell line already expressing a  $\beta$ -Gal gene with an expression vector comprising human matrilysine gene and a neomycine resistance gene<sup>50</sup>. This transfection greatly increased the fusion capacity *in vitro* and the generation of fibers *in vivo*. Expression of  $\beta$ -Gal gene was measured. The clone Imm 7 Matrilysine was compared to the same clone (Imm7) transfected solely with the neomycine resistance gene. As seen from figure 2, the injection of 500,000 cells in the anterior tibialis muscle of recipient mice (non irradiated and non injected with a

- 32 -

myotoxic agent such as notexin) resulted in the average presence (n = 8 mice) of 39 positive fibers for beta-galactosidase following the injection of the clone expressing matrilysine, while no fiber has been observed with the control clone, three (3) weeks after the injection.

Fourth experiment: Tumoral myoblasts obtained from G8 mice transfected with the same construct (matrilysine and neomycine recombinant) and labelled with a fluorescent die (PKH26) have been allowed to migrate for eight (8) days following injection in the anterior tibialis muscle of recipient mice. The distance of migration was equivalent to three to four times the distance observed with the control construct.

When myoblasts are cloned, which results in the removal of fibroblasts, it is believed that recombinant myoblasts expressing a metalloprotease gene product could be useful in increasing further the success of transplantation *per se* or along with the increase due to the preconditioning step with a growth factor.

Alternatively, metalloproteases could be directly injected with the donor's myoblasts to increase the migration of the transplanted cells.

- 33 -

Although the present invention has been described hereinabove by way of preferred embodiments thereof, it can be modified, without departing from the spirit and nature of the subject invention as defined in  
5 the appended claims.

- 34 -

**REFERENCES**

1. Allen RE and Boxhorn AL: Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor 1, and fibroblast growth factor. J. Cell. Physiol. 1989;138: 311-315.  
5
2. Anderson JE, Kakulas BA, Jacobsen PF, Johnsen RD, Kornegay JN and Grounds MD: Comparison of basic growth factor in x-linked dystrophin-deficient myopathies of human, dog and mouse. Growth Factor 1993; 9: 107-121.  
10
3. Anderson JE, Liu L and Kardami E: Distinctive patterns of basic fibroblast growth factor (bFGF) distribution in degenerating and regenerating areas of dystrophic (mdx) striated muscles. Develop Biol  
15 1991;147: 96-109.
4. Austin L, Bower J, Kurek J and Vakakis N: Effect of leukaemia inhibitory factor and other cytokines on murine and human myoblast proliferation. J. Neurol.. Sci. 1992;112:185-191.

- 35 -

5. Austin L and Burgess AW: Stimulation of myoblast proliferation in culture by leukaemia inhibitory factor and other cytokines. J Neurol. Sci 1991;101: 193-197.
6. Arahata K, Ishiura S, Tsukahara T, Suhara Y, Eguchi  
5 C, Ishihara T, Nonaka I, Ozawa E and Sugita H:  
Immunostaining of skeletal and cardiac muscle membrane  
with antibody against Duchenne muscular dystrophy  
peptide. Nature 1988; 333: 861-863.
7. Beauchamp JR, Morgan JE, Pagel CN, Partridge TA:  
10 Quantitative studies of the efficacy of myoblast  
transplantation. Muscle and Nerve Supp. 1, S261, 1994.
8. Bischoff R: A satellite cell mitogen from crushed  
muscle. Dev. Biol. 1986; 115:140-147.
9. Chen G and Quinn LS: Partial characterization of  
15 skeletal myoblast mitogen in mouse crushed muscle  
extract. J Cell Physiol 1992;153: 563-574.
10. Chen M, Li HJ, Fang Q, Goodwin TG, Florendo JA and  
Law PK: Dystrophin cytochemistry in mdx mouse muscle  
injected with labeled normal myoblasts. Cell Transpl  
20 1992;1: 17-22.

- 36 -

11. Clarke MSF, Khakee R and McNeil PL: Loss of cytoplasmic basic fibroblast growth factor from physiologically wounded myofibers of normal and dystrophic muscle. J Cell Sci 1993;106: 121-133.
- 5 12. Clegg CH, Linkhart TA, Olwin BB and Hauschka SD: Growth factor control of skeletal muscle differentiation: Commitment to terminal differentiation occurs in G1 phase and repressed by fibroblast growth factor. J Cell Biol 1987; 105: 949-956.
- 10 13. DiMario J, Buffinger N, Yamada S and Strohman RC: Fibroblast growth factor in the extracellular matrix of dystrophic (mdx) mouse muscle. Science 1989; 244: 688-690.
- 15 14. DiMario J and Strohman RC: Satellite cells from dystrophic (mdx) mouse muscle are stimulated by fibroblast growth factor in vitro. Differentiation 1988; 39: 42-49.
- 20 15. Florini JR and Magri KA: Effect of growth factors on myogenic differentiation. Am J Physiol 1989; 256: C701-C711.

- 37 -

16. Grounds MD: Towards understanding skeletal muscle regeneration. Path Res Pract 1991;187:1-22.
17. Gussoni E, Pavlath PK, Lanctot AM, Sharma K, Miller RG, Steinman L and Bland HM: Normal dystrophin  
5 transcripts detected in DMD patients after myoblast transplantation. Nature 1992; 356: 435-438.
18. Hallauer SM, Bradshaw HW and Hasting KEM: Complex fiber-type specific expression of fast skeletal muscle troponin I gene constructs in transgenic mice.  
10 Development 1993;119: 691-701.
19. Hoffman EP, Brown RH and Kunkel LM: Dystrophin: the protein product of Duchenne muscular dystrophy locus. Cell 1987; 51: 919-928.
20. Hsu H-Y, Nicholson AC and Hajjar DP: Basic  
15 Fibroblast Growth Factor-induced Low Density Lipoprotein Receptor Transcription and Surface Expression. J. Biol. Chem. 1994; 269: 9213-9220.
21. Huard J, Ascadi G, Jani A, Massi B: Gene transfer into mdx skeletal muscle by isogenic, genetically



- 38 -

labelled myoblasts. Muscle and Nerve, Suppl. 1, S260, 1994.

22. Huard J, Bouchard JP, Roy R, Malouin F, Dansereau G, Labrecque C, Albert N, Richards CL, Lemieux B and Tremblay JP: Human myoblast transplantation: preliminary results of 4 cases. Muscle and Nerve 1992; 15: 550-560.
23. Huard J, Verreault S, Roy R, Tremblay M and Tremblay JP: High efficiency of muscle regeneration following human myoblast clone transplantation in SCID mice. J Clin Invest 1994; 93: 586-599.
24. Karpati G, Ajdukovic D, Arnold D, Gledhill RB, Guttmann R, Holland P, Koch PA, Shoubbridge E, Spence D, Vanasse M, Watters GV, Abrahamowicz M, Duff C and Worton RG: Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol 1993; 34: 8-17.
25. Karpati G, Pouliot Y, Zubrzycka-Gaarn E, Carpenter S, Ray PN, Worton RG and Holl P: Dystrophin is expressed in mdx skeletal muscle fibers after normal myoblast implantation. Am J Pathol 1989; 135: 27-32.

- 39 -

26. Kinoshita I, Huard J and Tremblay JP: Utilization of myoblasts from transgenic mice to evaluate the efficacy of myoblast transplantation. Muscle and Nerve 1994;17:975-980.
- 5 27. Kinoshita I, Vilquin JP, Guérette B, Asselin I, Roy R, Tremblay JP. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle and Nerve 1994; 17: 1407-1415.
- 10 28. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C and Kunkel LM: Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987; 50: 509-517.
- 15 29. Labrecque C, Roy R and Tremblay JP: Immune reaction after myoblast transplantation in mouse muscle. Transplant Proc 1992; 24: 2889-2892.
- 20 30. Law PK, Bertorini TE, Goodwin TG, Chen M, Fang Q, Kirby DS, Florendo JA, Herrod HG and Golden GS: Dystrophin production induced by myoblast transfer therapy in Duchenne muscular dystrophy. Lancet 1990; 336: 114-115.

- 40 -

31. Lowe WL, Yorek MA and Teasdale RM: Ligands That Activate Protein Kinase-C Differ in Their Ability to Regulate Basic Fibroblast Growth Factor and Insulin-Like Growth Factor-I Messenger Ribonucleic Acid Levels..  
5 Endocrinology 1993; 132: 1593-1602.
32. Morgan JE: Cell and gene therapy in Duchenne muscular dystrophy. Human Gene Therapy 1994; 5:165-173.
33. Morgan JE, Pagel CN, Sherratt T and Partridge T: Long-term persistence and migration of myogenic cells  
10 injected into preirradiated muscles of mdx mice. J Neurol Sci 1993;115:191-200.
34. Partridge TA: Myoblast transfer: a possible therapy for inherited myopathies? Muscle and Nerve 1991;14:197-212.
- 15 35. Partridge TA, Morgan JE, Coulton GR, Hoffman EP and Kunkel LM: Conversion of mdx myofibers from dystrophin negative to positive by injection of normal myoblasts. Nature 1989; 337: 176-179.
- 20 36. Patte C and Blanquet PR: Possible involvement of arachidonic acid metabolites in the synergistic action

- 41 -

of endothelial mitogenesis by basic fibroblast growth factor and phorbol ester. Cell. Mol. Biol. 1992; 38: 429-436.

37. Sugita H, Arahata K, Ishiguro T, Suhara Y, Tsukahara  
5 T, Ishiura S, Eguchi C, Nonaka I and Ozawa E: Negative immunostaining of Duchenne muscular dystrophy (DMD) and mdx muscle surface membrane with antibody against synthetic peptide fragment predicated from DMD cDNA. Proc Japan Acad 1988; 64: 37-39.

10 38. Tremblay JP, Bouchard JP, Malouin F, Théau D, Cottrell F, Collin H, Rouche A, Gilgenkrantz S, Abbadi N, Tremblay M, Tomé FMS and Fardeau M: Myoblast transplantation between monozygotic twin girl carrier of Duchenne muscular dystrophy. Neuromusc. Disord. 1993;  
15 3(5/6): 583-592.

39. Tremblay JP, Malouin F, Roy R, Huard J, Bouchard JP, Satoh A and Richards CL: Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne  
20 muscular dystrophy . Cell Transplantation 1993; 2: 99-112.

- 42 -

40. Tienari J, Pertovaara L. Saksela O, Lehtonen E and Vartio T: Increased expression of the matrix metalloproteinase 2 in differentiating tera 2 human embryonal carcinoma cells. J. Cancer 1994; 56: 219-223.
- 5 41. Vaidya TB, Rhodes SJ, Traparowsky EJ and Konieczny SF: Fibroblast growth factor and transforming growth factor  $\beta$  repress transcription of myogenic regulatory gene MyoD1. Molecular Cellular Biol 1989; 9: 3576-3579.
- 10 42. Vilquin J-T, Asselin I, Guérette, B Kinoshita I, Lille S. Roy R and Tremblay JP: Myoblast allotransplantation in Mice: Degree of Success Varies Depending on the Efficacy of Various Immunosuppressive Treatments. Transpl. Proc. 1994; 26: 3372-3373.
- 15 43. Wakeford S, Watt DJ, Partridge TA: X-irradiation improves mdx mouse muscle as a model of myofiber loss in DMD. Muscle and Nerve 1991; 14: 42-50.
44. Overall CM and Sodek: Concanavalin A induces the expression of metalloprotease by fibroblasts. Brit. J. Surgery 1996; 83: 251-254.

- 43 -

45. Stetler Stevenson W.G., Liotta L. A., Kleiner Jr D. E.: Extracellular Matrix 6: Role of matrix metalloproteinase in tumor invasion and metastasis. FASEB J., 1993, 7: 1434-1441.
- 5      46. Gaire M., Magbanua Z., McDonnell S., Mcneil L., Lovett D., and Matrisian L.: Structure and Expression of the Human Gene for the Matrix Metalloproteinase Matrilysine. JBC, 1994, 269: 2031-2040.
- 10     47. Sato H., Takino T., Kinoshita T., Imai K., Okada Y., Stetler Stevenson W.G., Seiki M.: Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloprotenase. FEBS Letters, 1996, 385: 238-240.
- 15     48. Khérif S., Lafuma C., Dehaupas M., Lackar S., Verdière-Sahumé M., Fardeau M., Alameddine H.: Expression des métalloprotéases 2 et 9 au cours de la dégénérescence et de la régénération du muscle squelettique chez la souris normale et mdx. Colloque sur les maladies neuromusculaires, 1995.
- 20     49. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler Stevenson W.G., Quaranta V.: Induction of Cell

- 44 -

Migration by Metalloprotease-2 Cleavage of lamain-5.  
Science, 1997, 277: 225-228.

50. Powell W., Knox D., Navre M., Grogan T., Kittelson  
J., Nagle R., and Bowden T.: Expression of the  
5 Metalloprotenase Matrilysin in DU-145 Cells Increases  
Their Invasive Potential in severe Combined  
Immunudefficient Mice. Cancer Res., 1993, 53: 417-422.

- 45 -

WHAT IS CLAIMED IS:

1. A method for increasing the number of transplanted functional donor's myoblasts which are fused with non-functional myoblasts of a recipient individual suffering of a myopathy, which comprises the step of growing *in vitro* said donor's myoblasts in a appropriate culture medium in the presence of fibroblasts and of an agent inducing the secretion of an enzyme involved in extracellular matrix destruction, prior to injecting a mixture comprising said donor's myoblasts and induced enzyme into said recipient individual's muscle, whereby a functional muscle is at least in part restored.

2. A method for increasing the number of transplanted functional donor's myoblasts which are fused with non-functional myoblasts of a recipient individual suffering of a myopathy, which comprises the steps of: inserting into said donor's myoblasts a gene construct capable of expressing an enzyme involved in extracellular matrix destruction, obtaining thereby recombinant donor's myoblasts, and growing said recombinant donor's myoblasts in an appropriate culture medium, prior to injecting said recombinant donor's



- 46 -

myoblasts into said recipient individual's muscle,  
whereby a functional muscle is at least in part  
restored.

3. A method of claim 1, wherein said  
5 enzyme is a metalloprotease.

4. A method of claim 2, wherein said  
enzyme is a metalloprotease.

5. A method of claim 3, wherein said  
metalloprotease is Gelatinase A or Matrilysine.

10 6. A method of claim 4, wherein said  
metalloprotease is Gelatinase A or Matrilysine.

7. A method of claim 1, 3 or 5, wherein  
said agent is Concanavalin A or phorbol ester.

15 8. A method as defined in any one of  
claims 1 to 7, wherein said culture medium further  
comprises a growth or trophic factor for increasing the  
multiplication of said donor's myoblasts.

- 47 -

9. A method as defined in claim 8,  
wherein said growth or trophic factor is selected from  
the group consisting of basic fibroblast growth factor  
(bFGF), insulin growth factor I, transferrin,  
5 platelet-derived growth factor, epidermal growth factor,  
adrenocorticotrophin, macrophage colony-stimulating  
factor, protein kinase C activators, agonists thereof,  
and combinations thereof.

10. A method as defined in claim 9,  
10 wherein said factor is bFGF.

11. A method as defined in any one of  
claims 1, 3, 5, 7, 8, 9, and 10, wherein said donor's  
myoblasts are obtained for a primary myoblast culture  
resulting from culturing a cell dispersion of donor's  
15 muscle biopsy.

12. A method as defined in claim 11,  
wherein said primary myoblast culture is grown in the  
presence of 100 ng of recombinant human basic fibroblast  
growth factor per milliliter of culture medium for a  
20 period of time of about 48 hours before transplantation.

- 48 -

13. A method as defined in claim 11,  
wherein said primary myoblast culture is grown in the  
presence of 100 ng of recombinant human basic fibroblast  
growth factor and 20  $\mu$ g Concanavalin A per milliliter of  
5 culture medium for a period of time of about 48 hours  
before transplantation.

14. A method as defined in any one of  
claims 1 to 13, wherein said myopathy is Duchenne  
muscular dystrophy.


10 15. A method for increasing the number of  
transplanted functional donor's cells which are fused  
with corresponding non-functional cells of a recipient  
individual's tissue, which comprises the steps of:  
inserting into said donor's cells a gene construct  
15 capable of expressing an enzyme involved in  
extracellular matrix destruction, obtaining thereby  
recombinant donor's cells, and growing said recombinant  
donor's cells in an appropriate culture medium, prior to  
injecting said recombinant donor's cells into said  
20 recipient individual's tissue, whereby a functional  
tissue is at least in part restored.

- 49 -

16. A method of claim 15, wherein said enzyme is a metalloprotease.

17. A method of claim 16, wherein said metalloprotease is Matrilysine or Gelatinase A.

1/2



2/2




FIG. 2

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 97/00774

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N5/08 C12N5/10 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 28541 A (UNIVERSITE LAVAL) 19 September 1996 see the whole document ---	1-17
A	KINOSHITA I ET AL: "Pretreatment of myoblast cultures with basic fibroblast growth factor increases the efficacy of their transplantation in mdx mice." MUSCLE & NERVE 18 (8). 1995. 834-841, XP000572291 see the whole document ---	1-17
A	WO 91 12329 A (BOARD OF THE REGENTS, THE UNIVERSITY OF TEXAS) 22 August 1991 see the whole document ---	1-17
A	US 5 435 999 A (AUSTIN L.) 25 July 1995 see the whole document ---	1-17
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

2 February 1998

Date of mailing of the international search report

23.02.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Moreau, J



# INTERNATIONAL SEARCH REPORT

Int. onal Application No  
PCT/CA 97/00774

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CRINNION J. N. ET AL.: "Role of neutrophil-endothelial adhesion in skeletal muscle reperfusion injury" BRITISH JOURNAL OF SURGERY, vol. 83, no. 2, February 1996, pages 251-254, XP002054086 cited in the application see the whole document</p> <p>---</p>	1-17
A	<p>POWELL W.C.: "Expression of the Metalloproteinase Matrilysin in DU-145 Cells Increases Their Invasive Potential in severe Combined Immunodeficient Mice" CANCER RESEARCH, vol. 53, no. 2, 15 January 1993, pages 417-422, XP002054097 cited in the application see the whole document</p> <p>-----</p>	2-17



## INTERNATIONAL SEARCH REPORT

Int. application No.  
PCT/CA 97/00774

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Remark : Although claims 1-17 are directed to a method of treatment of the human/animal body , the search has been carried out and based on the alleged effects of the compound/composition.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 97/00774

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9628541 A	19-09-96	AU 4934496 A	02-10-96
		EP 0815205 A	07-01-98
-----			
WO 9112329 A	22-08-91	AU 7312891 A	03-09-91
		US 5466676 A	14-11-95
-----			
US 5435999 A	25-07-95	AT 138267 T	15-06-96
		AU 624284 B	04-06-92
		AU 6896791 A	26-06-91
		WO 9107992 A	13-06-91
		CA 2045630 A	25-05-91
		DE 69027123 D	27-06-96
		DE 69027123 T	24-04-97
		EP 0502081 A	09-09-92
-----			